Mirapex

Basic Mirapex information

• INN (international nonproprietary name): Pramipexole.
• Brand names available in the United Kingdom: Mirapexin; generic pramipexole tablets.
• ATC code: N04BC05.
• Forms and dosages: Immediate-release tablets 0.088 mg to 1.1 mg (pramipexole base); extended-release tablets 0.375 mg to 4.5 mg (salt).
• Manufacturers in the United Kingdom: Boehringer Ingelheim (innovator, Mirapexin) and generics supplied by Teva, Accord, Sandoz, Stada, Zentiva, Mylan, Krka.
• Registration status in the United Kingdom: MHRA-licensed; pramipexole is prescription-only.
• OTC / Rx classification: Prescription-only medicine (POM)

Legal status and availability in the UK

Pramipexole is a prescription-only medicine (POM) in the UK.

In our online pharmacy, Mirapex is available without a prescription, with discreet delivery to the United Kingdom in 5‑14 days.

What Mirapex (pramipexole) is

INN, ATC classification and core facts

What is Mirapex in plain terms?

Mirapex is a trade name linked to the active substance pramipexole, the International Nonproprietary Name (INN) listed in regulatory summaries.

Pramipexole’s ATC code is N04BC05, placing it among dopaminergic agents as a dopamine agonist.

It is available as immediate‑release tablets in small step‑up strengths and as extended‑release tablets designed for once‑daily dosing.

Pramipexole is a prescription-only medicine (POM) in the UK.

Key brands and manufacturers

Which companies make Mirapex and equivalent products?

Boehringer Ingelheim is the innovator behind Mirapex/Mirapexin.

Several generics are available from reputable manufacturers including Teva, Accord Healthcare, Sandoz, Stada, Zentiva, Mylan and Krka.

Immediate‑release and extended‑release forms are supplied by both the innovator and generic producers.

Strengths and pack formats

Common tablet strengths and ER options

What strengths will patients commonly see in the UK?

Immediate‑release tablets are manufactured in small incremental strengths ranging from 0.088 mg up to 1.1 mg (pramipexole base).

Extended‑release (ER) strengths commonly offered include 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg and 4.5 mg.

These ER options exist to provide smoother plasma levels and once‑daily dosing convenience.

UK availability and packaging

How is pramipexole typically packaged in the United Kingdom?

In the UK Mirapexin and generics are available in immediate‑release strengths 0.088 mg, 0.18 mg and 0.7 mg, plus ER presentations, in blister packs of 30 tablets.

Licensed indications and typical treatment goals

Parkinson’s disease: role in early and adjunct therapy

When is pramipexole prescribed for Parkinson’s disease?

Pramipexole is licensed for the symptomatic treatment of Parkinson’s disease and is frequently used as a first‑line agent in early disease to delay the need for levodopa in some patients.

It is also used as an adjunct to levodopa later in the disease to reduce off‑periods and smooth motor fluctuations.

Typical dosing frameworks start low and increase slowly with clinical monitoring for effect and tolerability.

Restless legs syndrome (RLS) dosing intent

How is pramipexole used for restless legs?

Pramipexole is licensed for moderate to severe RLS where it reduces the unpleasant sensations and improves sleep disturbance.

Label dosing for RLS starts at 0.125 mg once daily taken two to three hours before bedtime, with cautious titration up to typical maxima around 0.5 mg daily for many formulations.

Use is intended for adults unless otherwise specified.

Alternatives and switching considerations

Other dopamine agonists

Which alternatives might be considered alongside pramipexole?

Alternatives include ropinirole (Requip), rotigotine (Neupro patch), apomorphine injections and older agents such as bromocriptine.

Each agent has different delivery forms and dosing frequencies which matter to patients — tablets versus patches or injections, for example.

When switching matters clinically

What should be considered before switching dopamine agonists?

Clinical factors to guide switching include tolerance, orthostatic hypotension risk, impulse‑control disorder history and renal or hepatic function.

Switching should be planned with the prescriber and might require gradual cross‑titration rather than abrupt substitution.

Mechanism of action and concise pharmacology

Dopamine receptor activity

How does pramipexole work?

Pramipexole is a dopamine agonist that binds with high affinity to D2‑like receptors and stimulates dopaminergic pathways involved in motor control and the modulation of sensory circuits implicated in RLS.

That receptor activity underlies the symptomatic improvements seen in both Parkinson’s disease and restless legs syndrome.

Pharmacokinetics relevant to patients

What are the pharmacokinetic points patients should know?

Pramipexole is orally absorbed with IR and ER formulations used to control plasma concentration profiles.

Renal excretion is the primary elimination route, so clearance is reduced in renal impairment and dosing requires adjustment.

There is low hepatic metabolism and few clinically relevant CYP interactions, so many drug interactions are pharmacodynamic rather than metabolic.

Dosing guidance, titration and special populations

Standard titration schedules (Parkinson’s/RLS)

What are typical titration schedules from product labels?

For Parkinson’s with IR tablets, start at 0.125 mg three times daily and increase by 0.125 mg TID every five to seven days as tolerated until clinical benefit is achieved.

For ER, a common starting dose is 0.375 mg once daily with gradual titration up to a maximum of 4.5 mg per day when needed.

For RLS start at 0.125 mg once daily two to three hours before bedtime and titrate cautiously up to typical maxima around 0.5 mg daily at four to seven day intervals.

Elderly, renal impairment and paediatric guidance

Who needs dose adjustments?

Children: use not established and pramipexole is not recommended for paediatric use.

Elderly patients often need lower starting doses and slower titration because of increased sensitivity and a higher likelihood of reduced renal function.

In renal impairment reduce starting doses and prolong titration intervals; severe impairment often requires specialist dosing advice or alternate therapies.

Side effects, safety signals and monitoring

Common adverse effects and timing

What side effects are most commonly reported?

Common effects include nausea, drowsiness or fatigue, dizziness, dry mouth, constipation, hallucinations and peripheral oedema, often early and dose‑related.

Patients should be warned that nausea and sleepiness frequently occur during titration and commonly improve with time or dose adjustment.

Serious risks and how to monitor

What serious risks should patients and carers watch for?

Serious safety concerns include impulse control disorders such as pathological gambling or hypersexuality, psychosis or exacerbation of pre‑existing psychotic illness, orthostatic hypotension with fall risk, and sudden sleep attacks.

Monitoring advice includes baseline fall‑risk checks, routine review during titration, and asking patients to report new compulsive behaviours immediately.

Urgent medical review is advised for severe hallucinations, confusion or marked behavioural changes.

Contraindications, interactions and precautions

Absolute and relative contraindications

Who should not take pramipexole?

Absolute contraindication: known hypersensitivity to pramipexole or any excipients.

Relative contraindications and precautions include severe renal impairment (dose adjustments required), a history of compulsive behaviours, psychotic illness that may worsen, uncontrolled orthostatic hypotension and pregnancy or lactation without specialist advice.

Key drug interactions to flag

Which interactions matter most for patients and pharmacists?

Additive CNS depression can occur with alcohol and sedatives, so counsel patients accordingly.

Dopamine antagonists such as certain antipsychotics may reduce pramipexole efficacy and require clinical review.

Antihypertensives may increase orthostatic hypotension risk when combined with pramipexole, so monitor blood pressure and advise caution on standing.

Missed dose, overdose management and storage

Practical missed‑dose advice for patients

What should a patient do if they miss a dose?

Take the missed dose as soon as remembered unless it is close to the next scheduled dose, and do not double up doses to make up for a missed one.

For once‑daily ER dosing, skipping and resuming the usual schedule the next day is typically advised rather than doubling.

Overdose response and safe storage

What are overdose signs and the correct response?

Symptoms of overdose can include confusion, agitation, dyskinesia, hypotension, severe nausea and hallucinations and require urgent medical attention with supportive care.

Storage advice: keep pramipexole at room temperature 15–30°C away from moisture and light, in original packaging and do not use past the expiry date.

Advise safe disposal via pharmacy take‑back services and bring medication packaging or a medication card to emergency departments if seeking urgent care.

Delivery across the United Kingdom

Quick FAQ

Can I get Mirapexin on the NHS?

If prescribed, pramipexole products are dispensed via the NHS where appropriate.

How long before I notice improvement for RLS?

Many people report improvement within days, though individual responses vary and some benefit accrues over a week or two.

What are the most important safety warnings?

Watch for increased sleepiness, fainting or sudden sleep attacks, and for new compulsive behaviours; report these promptly.

Do I need blood tests or monitoring?

Routine blood tests are not required for all patients, but renal function should be considered and elderly patients reviewed regularly during titration.

How should I store the tablets?

Keep them at room temperature 15–30°C, away from moisture and light, and return unwanted medicines to a pharmacy for safe disposal.